ArticleJournal of gynecologic oncology2019
A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma.
Article in Journal of gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Early risk prediction in endometrial cancer using biomarker and machine learning models: a systematic review and meta-analysis protocol.Systematic reviews · 2026Pooled it
- Article
- Nomogram Based on Pan-Immune Inflammation Value and Clinicopathological Parameters for Predicting the Recurrence of Endometrial Cancer and Providing Postoperative Prognostic Management.Annals of surgical oncology · 2026Article
- Predictive value of IGF2BP2 for endometrial cancer recurrence: a multicenter study.Frontiers in oncology · 2026Article
- A novel nomogram incorporating preoperative systemic inflammatory response index and clinicopathological parameters for predicting lymph node metastasis in endometrial cancer.Frontiers in oncology · 2026Article
- Small bowel metastasis from endometrial cancer presenting as a bowel obstruction: A case report with literature review.DEN open · 2025Article
- New online dynamic nomograms to predict recurrence-free and overall survival after resection of endometrial cancer: a single-institution retrospective cohort study.Archives of gynecology and obstetrics · 2024Article
- The prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer.Frontiers in oncology · 2024Article
- Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia.Archives of gynecology and obstetrics · 2023Article
- Application value of Ki67 and serum CA125 in the deep myometrial invasion of endometrial adenocarcinoma.BMC cancer · 2023Article
- Consistency of P53 immunohistochemical expression between preoperative biopsy and final surgical specimens of endometrial cancer.Frontiers in oncology · 2023Article
- Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer.Scientific reports · 2022Article
- A Nomogram Model for Predicting Recurrence of Stage I-III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and Traditional Classical Predictors.Journal of inflammation research · 2022Article
- [Using Immunohistochemical Markers and Clinicopathological Factors to Predict the Prognostic Survival of Different Types of Endometrial Cancer Recurrence].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Article
- Postoperative Systemic Immune-Inflammation Index (SII): A Superior Prognostic Factor of Endometrial Cancer.Frontiers in surgery · 2021Article
- Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma.Frontiers in oncology · 2021Article
- Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.Gynecologic oncology · 2020Observational
- Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.European journal of cancer (Oxford, England : 1990) · 2020Observational
- Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a 3-year recurrence prediction score (RPS) system for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma.
methodsWe reviewed 427 patients with International Federation of Gynecology and Obstetrics staging I-II endometrial carcinoma underwent surgery without any adjuvant therapy from 2005 to 2013. The patients were divided into 2 groups: the test cohort (n=251) comprising those who underwent surgery in odd-numbered years, and the validation cohort (n=176) comprising those who underwent surgery in even-numbered years. Multivariate analysis was performed using 7 candidate predictors to identify the risk factors for 3-year recurrence-free interval (RFI) in the test cohort. Each risk factor was scored based on logistic regression analyses of the test data set, and the sum of the risk factor scores was defined as the RPS system. We then applied the system in the validation cohort.
resultsMultivariate analysis revealed that the significant risk factors were age ≥60 years, pathological type II, positive cervical stromal invasion, and positive peritoneal cytology. In the test cohort, the 3-year RFI rates were 100%, 95.8%, 79.9%, and 33.3% for RPSs of 0, 1, 2, and 3, respectively. In the validation cohort, the 3-year RFI was significantly higher in the low-RPS group (RPS 0 or 1) than in the high-RPS group (RPS 2 or 3) (95.2% vs. 79.9%, p<0.01).
conclusionsThe RPS system shows significant reproducibility for predicting the baseline risk of recurrence. The system could potentially impact the choice of adjuvant therapy for stage I-II endometrial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.